H.R. 1117 explained · 119th Congress · Pending in Congress
Responsibility in Drug Advertising Act of 2025
Cosponsors: none · per Congress.gov, 2026-10-12
Introduced: 2025-02-07
Latest action (2025-02-07): Referred to the House Committee on Energy and Commerce.
What H.R. 1117 does, in plain terms
Responsibility in Drug Advertising Act of 2025 This bill prohibits direct-to-consumer advertising of new drugs during the first three years following their approval by the Food and Drug Administration (FDA). Direct-to-consumer advertising includes advertising via social media. Upon request from a drug’s sponsor, the FDA may waive the prohibition during the third year following a drug’s approval if it determines that the direct-to-consumer advertising of the drug would have an affirmative value to public health. Conversely, the FDA may prohibit such advertising beyond the three-year period following approval if it determines that the drug has significant adverse health effects based on post-approval studies, adverse event reports, and other appropriate resources. The prohibition applies to new drugs approved beginning one year before the bill’s enactment.
Official summary by the Congressional Research Service, via Congress.gov.
Constitution Index
“VFA Constitution grade”
Not graded yet
H.R. 1117 has not been graded yet. New measures with an official summary are graded daily under the published rubric.
What should pass
“VFA SI Solution”
No solution yet
A sourced SI draft appears here once it passes automated checks (Constitution citation, source verification, independent SI critic). How publication works.
For journalists and bloggers
“Embed this grade”
Free to use with the link back. The badge and card update when the grade changes. Embed terms →
